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Abstract
Background: Management of type 2 diabetes with metformin often does not provide adequate glycemic control,
thereby necessitating add-on treatment. In a 24-week clinical trial, dapagliflozin, an investigational sodium glucose
cotransporter 2 inhibitor, improved glycemic control in patients inadequately controlled with metformin. The
present study is an extension that was undertaken to evaluate dapagliflozin as long-term therapy in this
population.
Methods: This was a long-term extension (total 102 weeks) of a 24-week phase 3, multicenter, randomized,
placebo-controlled, double-blind, parallel-group trial. Patients were randomly assigned (1:1:1:1) to blinded daily
treatment (placebo, or dapagliflozin 2.5 to 5, or 10 mg) plus open-label metformin (≥1,500 mg). The previously
published primary endpoint was change from baseline in glycated hemoglobin (HbA1c) at 24 weeks. This paper
reports the follow-up to week 102, with analysis of covariance model performed at 24 weeks with last observation
carried forward; a repeated measures analysis was utilized to evaluate changes from baseline in HbA1c, fasting
plasma glucose (FPG), and weight.
Results: A total of 546 patients were randomized to 1 of the 4 treatments. The completion rate for the 78-week
double-blind extension period was lower for the placebo group (63.5%) than for the dapagliflozin groups (68.3% to
79.8%). At week 102, mean changes from baseline HbA1c (8.06%) were +0.02% for placebo compared with -0.48%
(P = 0.0008), -0.58% (P <0.0001), and -0.78% (P <0.0001) for dapagliflozin 2.5 to 5, and 10 mg, respectively. In
addition, all dapagliflozin groups had sustained reductions from baseline in FPG (-1.07 to -1.47 mmol/l) and body
weight (-1.10 to -1.74 kg) at 102 weeks, whereas increases were noted in placebo-treated patients for both of these
outcomes. Events of hypoglycemia were rare and were not severe. Evidence suggestive of genital infection was
reported in 11.7% to 14.6% of dapagliflozin patients and 5.1% of placebo patients, with one related discontinuation
(dapagliflozin 5 mg). Evidence suggestive of urinary tract infection was reported in 8.0% to 13.3% of dapagliflozin
patients and 8.0% of placebo patients, with one related discontinuation (dapagliflozin 2.5 mg).
Conclusions: Dapagliflozin added to metformin for 102 weeks enabled sustained reductions in HbA1c, FPG, and
weight without increased risk of hypoglycemia in patients with type 2 diabetes who were inadequately controlled
on metformin alone.
Trial registration: ClinicalTrials.gov: NCT00528879
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Background
Treatment of type 2 diabetes often begins with lifestyle
management and/or metformin [1]. As b-cell function
declines in the presence of insulin resistance, this makes
maintenance of glycemic control challenging and usually
necessitates add-on therapies. Because metformin acts to
improve insulin sensitivity [2], the addition of therapy utiliz-
ing an insulin-independent pathway may be advantageous.
Inhibition of sodium-glucose cotransporter 2 (SGLT2)
represents a novel approach to reduce hyperglycemia
independently of insulin secretion or action [3-6].
SGLT2, located in the renal proximal tubule, reabsorbs
most of the filtered glucose [7] and its inhibition repre-
sents a new pharmacotherapy for the treatment of type 2
diabetes. Dapagliflozin, a potent and selective SGLT2
inhibitor, has been shown to improve glycemic control in
patients with type 2 diabetes when used as monotherapy
[8] or in combination with metformin [9], sulfonylureas
[10,11], thiazolidinedione [12], or insulin [6,13].
When dapagliflozin was added to metformin for 24
weeks in patients inadequately controlled on metformin
alone (glycated hemoglobin (HbA1c) ≥7% and ≤10%),
there was a dose-related mean reduction in HbA1c by
-0.67% with dapagliflozin 2.5 mg, -0.70% with dapagliflo-
zin 5 mg, and -0.84% with dapagliflozin 10 mg compared
to -0.3% with placebo [9]. The present report describes a
long-term double-blind extension of this study to exam-
ine the effectiveness and safety of dapagliflozin add-on to
metformin for 102 weeks in patients with type 2 diabetes
inadequately controlled on metformin monotherapy.
Methods
A detailed description of the 24-week methods was pub-
lished previously [9]. The 78-week extension is described
below. This double-blind, parallel-group, placebo-
controlled multicenter study recruited patients from 80
sites in Argentina, Brazil, Canada, Mexico, and USA. The
study was performed in accordance of the Declaration of
Helsinki and Good Clinical Practice guidelines, and was
approved by the institutional ethics review board at each
site. The most frequently utilized boards were New Eng-
land Institutional Review Board, Wellesley, Massachu-
setts (29 sites in the USA) and IRB Services, Aurora,
Ontario (19 sites in Canada). All patients provided writ-
ten informed consent, which included consent for the
extension period.
Patients who completed the first 24-week period were
eligible to continue in a long-term, double-blind exten-
sion period to 102 weeks. During the extension period,
patients remained on their original randomly-assigned
(1:1:1:1) blinded treatment (placebo, or dapagliflozin 2.5
mg, 5 mg, or 10 mg) once daily and continued open-label
metformin (≥1,500 mg/day). Patients receiving rescue
therapy (primarily pioglitazone, or acarbose) during the
first 24 weeks continued to receive rescue therapy to 102
weeks. During the 78-week extension period, patients
were eligible to receive rescue medication if the HbA1c
value was >8.0% during weeks 24 to 50, was >7.5% during
weeks 50 to 76, or was >7.0% after week 76. These strict
rescue criteria ensured that even with a fully double-
blinded long-term design, the participants in all groups
were provided with adequate glycemic control. Although
the primary endpoint was the change from baseline in
HbA1c at 24 weeks [9], the prespecified exploratory
objectives in this study included assessment of the
change from baseline in HbA1c, fasting plasma glucose
(FPG), and body weight in the extension period for each
treatment group. The exploratory endpoints also
included the proportion of patients who achieved a thera-
peutic glycemic response defined as HbA1c <7.0% at
week 102. Safety outcomes included reported non-serious
and serious adverse events, discontinuation due to
adverse events, events of special interest, laboratory
abnormalities, and change in vital signs as described pre-
viously [9].
Formal statistical testing was performed for the pri-
mary endpoint and used an analysis of covariance
(ANCOVA) model at 24 weeks with the last observation
carried forward approach for missing week 24 data
excluding data after rescue [9]. At week 102, longitudi-
nal repeated measures analyses using observed data
without any data imputation were used to determine the
change in HbA1c, FPG, and total body weight from
baseline over time; the model included the categorical
fixed effects of treatment, week, and treatment-by-week
interaction as well as the continuous fixed covariates of
baseline measurement and baseline measurement-by-
week interaction. Rescue was added as an additional
categorical fixed effect in this mixed model when the
analysis was performed on data regardless of rescue.
Results
From the 546 originally randomized patients, 476 (87.2%)
continued into the 78-week extension period. Of these,
339 (71.2%) completed the 102-week study (Figure 1).
During the 78-week extension, the completion rate was
lower for the placebo group (63.5%) than for the dapagli-
flozin groups (68.3 to 79.8%). This was largely due to
more patients in the placebo group (23.5%) withdrawing
during the extension period for lack of efficacy, whereas
withdrawals were 13.3, 13.9, and 7.6% with dapagliflozin
2.5 mg, 5 mg, and 10 mg, respectively. Demographics and
baseline characteristics were balanced between treatment
groups as reported previously [9].
The mean HbA1c at baseline of all 546 randomized
patients was 8.06%. At week 102, the adjusted mean
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change from baseline in HbA1c was 0.02% (95% CI: -0.20
to 0.23) for placebo and -0.48% (95% CI: -0.68 to -0.29),
-0.58% (95% CI: -0.77 to -0.39), and-0.78% (95% CI: -0.97
to -0.60) for dapagliflozin 2.5 mg, 5 mg, and 10 mg,
respectively (Table 1). The reductions in HbA1c with
dapagliflozin were dose dependent and statistically signifi-
cant compared to placebo at week 102 (Figure 2A). When
excluding data after rescue, 20% (28/137) of patients in the
placebo group had observed data for HbA1c at week 102,
compared to 26% (36/137), 34% (47/137), and 42% (57/
135) of patients receiving dapagliflozin 2.5 mg, 5 mg, and
10 mg, respectively. At week 102, the proportion of
patients achieving HbA1c <7% was 20.7 (95% CI: 14.0 to
27.3), 26.4, (95% CI: 19.4 to 33.4), and 31.5% (95% CI: 23.7
to 39.3) for dapagliflozin 2.5 mg, 5 mg, and 10 mg, respec-
tively, vs 15.4% (95% CI: 9.5 to 21.3) for placebo (Table 1);
the adjusted proportion of patients achieving HbA1c <7%
was statistically significant for dapagliflozin at 5 mg (P =
0.0202) and 10 mg (P = 0.0014) compared to placebo.
Adjusted mean change from baseline in FPG was -0.58
mmol/l (95% CI: -0.97 to -0.19) for placebo and -1.07
mmol/l (95% CI: -1.42 to -0.72), -1.47 mmol/l (95% CI:
-1.78 to -1.16), and -1.36 mmol/l (95% CI: -1.65 to -1.07)
for the dapagliflozin 2.5 mg, 5 mg, and 10 mg, respectively,
at week 102 (Table 1). Adjusted mean change from baseline
in FPG was statistically significant for dapagliflozin 5 mg
(P = 0.0003) and 10 mg (P = 0.0012) compared to placebo.
The proportions of patients rescued or discontinued for
failing to achieve glycemic targets were 60.6% (83/137) for
placebo and 51.8% (71/137), 46.0% (63/137), and 42.2%
(57/135) for dapagliflozin 2.5 mg, 5 mg, and 10 mg, respec-
tively, at week 102.
As shown in Figure 2B, large increases in the urinary glu-
cose:creatinine ratio for the dapagliflozin groups were dose
dependent and maintained through to week 102. For total
body weight, when excluding data after rescue therapy, the
adjusted mean value decreased from baseline with dapagli-
flozin (-2.16 kg to -3.38 kg) and with placebo (-0.67 kg)
Figure 1 Trial profile over 102 weeks.
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through week 102. When including data after rescue,
recognizing that pioglitazone was the primary rescue medi-
cation, the adjusted mean value still decreased from base-
line with dapagliflozin (-1.10 kg to -1.74 kg) but increased
with placebo (1.36 kg) through week 102, and differences
between the dapagliflozin groups versus placebo were sta-
tistically significant at 102 weeks (Table 1, Figure 2C).
The proportions of patients who reported at least one
adverse event were similar across dapagliflozin groups
and the placebo group when including data after rescue
(Table 2). During the 78-week extension, three deaths
occurred (Table 2): two in the dapagliflozin 2.5 mg group
due to cardiopulmonary arrest and myocardial infarction,
and one death in the placebo group due to malignant
lung neoplasm. All three deaths were reported to be unli-
kely related or not related to the study treatment as
assessed by the investigator. The proportions of serious
adverse events through 102 weeks were similar across
dapagliflozin groups and the placebo group (Table 2).
Few patients reported adverse events that led to disconti-
nuation, and the proportion was similar in all treatment
groups (Table 2). No major episodes of hypoglycemia
occurred, and no discontinuations were due to hypogly-
cemia. The proportion of patients who reported at least
one event of hypoglycemia was similar across study
groups (Table 2).
As shown in Table 2, signs, symptoms, and other evi-
dence suggestive of urinary tract infection (UTI) occurred
at a higher rate in the dapagliflozin 10 mg group (13.3%)
compared to placebo (8.0%), dapagliflozin 2.5 mg group
(8.0%), and dapagliflozin 5 mg group (8.8%), with one dis-
continuation (dapagliflozin 2.5 mg). Signs, symptoms and
other evidence suggestive of vulvovaginitis, balanitis, and
related genital infection (not sexually transmitted) were
more common in the dapagliflozin groups (11.7% to 14.6%)
than placebo (5.1%) (Table 2) with one discontinuation
Table 1 Change from baseline in efficacy parameters
Placebo +
metformin (n = 137)
Dapagliflozin 2.5 mg +
metformin (n = 137)
Dapagliflozin 5 mg +
metformin (n = 137)
Dapagliflozin 10 mg +
metformin (n = 135)
HbA1c (%):a
Baseline (SD) 8.12 (0.96) 7.99 (0.90) 8.17 (0.96) 7.92 (0.82)
Change at week 24 (95% CI) -0.31 (-0.45 to -0.16) -0.65 (-0.79 to -0.51) -0.67 (-0.81 to -0.53) -0.82 (-0.96 to -0.68)
Difference vs PBO (95% CI) -0.35 (-0.55 to -0.14) -0.36 (-0.56, -0.16) -0.51 (-0.71, -0.31)
Change at week 102 (95% CI) 0.02 (-0.20 to 0.23) -0.48 (-0.68 to -0.29) -0.58 (-0.77 to -0.39) -0.78 (-0.97 to -0.60)
Difference vs PBO (95% CI) -0.50 (-079 to -0.21) -0.60 (-0.89 to -0.31) -0.80 (-1.08 to -0.52)
P vs PBO + MET 0.0008 <0.0001 <0.0001
FPG (mmol/l):a
Baseline (SD) 9.19 (2.58) 8.96 (2.39) 9.39 (2.72) 8.66 (2.15)
Change at week 24 (95% CI) -0.29 (-0.59 to 0.01) -0.95 (-1.23 to -0.67) -1.15 (-1.44 to -0.88) -1.23 (-1.51 to -0.94)
Difference vs PBO (95% CI) -0.66 (-1.07 to -0.25) -0.87 (-1.28 to -0.46) -0.94 (-1.35 to -0.53)
Change at week 102 (95% CI) -0.58 (-0.97 to -0.19) -1.07 (-1.42 to -0.72) -1.47 (-1.78 to -1.16) -1.36 (-1.65, -1.07)
Difference vs PBO (95% CI) -0.49 (-0.99 to 0.01) -0.89 (-1.37 to -0.41) -0.78 (-1.25 to -0.31)
P vs PBO + MET 0.0518 0.0003 0.0012
Weight (kg):a
Baseline (SD) 87.74 (19.24) 84.90 (17.77) 84.73 (16.26) 86.28 (17.53)
Change at week 24 (95% CI) -0.40 (-0.91 to 0.11) -1.96 (-2.47 to -1.44) -2.92 (-3.43 to -2.41) -2.65 (-3.16 to -2.13)
Difference vs PBO (95% CI) -1.55 (-2.27 to -0.84) -2.52 (-3.23 to -1.80) -2.24 (-2.96 to -1.53)
Change at week 102 (95% CI) 1.36 (0.53 to 2.20) -1.10 (-1.91 to -0.29) -1.70 (-2.48 to -0.91) -1.74 (-2.51 to -0.96)
Difference vs PBO (95% CI) -2.46 (-3.63 to -1.30) -3.06 (-4.21 to -1.92) -3.10 (-4.24 to -1.96)
P vs PBO + MET <0.0001 <0.0001 <0.0001
Percentage of patients with
HbA1c <7.0% (95% CI):b
At week 24 24.2 (17.4 to 30.9) 30.9 (23.4 to 38.4) 35.9 (28.4 to 43.5) 38.2 (30.3 to 46.1)
Difference vs PBO (95% CI) 6.7 (-3.2 to 16.6) 11.8 (1.9 to 21.6) 14.0 (3.9 to 24.1)
At week 102 15.4 (9.5 to 21.3) 20.7 (14.0 to 27.3) 26.4 (19.4 to 33.4) 31.5 (23.7 to 39.3)
Difference vs PBO (95% CI) 5.3 (-3.5 to 14.1) 11.0 (1.9 to 20.0) 16.1 (6.4 to 25.7)
P vs PBO + MET 0.2380 0.0176 0.0011
n indicates the number of randomized patients who took at least one dose of double-blind study medication. Data are means (SD) or means (95% CI). aAdjusted
mean change from baseline using longitudinal repeated measures, excluding data after rescue, except weight, which includes data after rescue. bPercentage
adjusted for baseline glycated hemoglobin (HbA1c). Patients discontinued or rescued prior to week t (t = 24 or 102) or missed measurements at week t are
considered not achieving glycemic response. DAPA = dapagliflozin; FPG = fasting plasma glucose; MET = metformin; PBO = placebo.
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Figure 2 Change from baseline in (A) glycated hemoglobin (HbA1c), (B) urinary glucose:creatinine ratio, and (C) body weight for
placebo (circles), dapagliflozin 2.5 mg (squares), dapagliflozin 5 mg (triangles), and dapagliflozin 10 mg (diamonds) groups all plus
metformin up to 102 weeks. Data are means (95% CI) obtained from longitudinal repeated measures analyses. Data for HbA1c exclude
patients who received rescue therapy to achieve the strict HbA1c requirements to remain in the trial. The urinary glucose:creatinine ratios also
exclude patients who received rescue therapy. Data for weight, however, include patients who received rescue therapy (pioglitazone),
demonstrating the ability of dapagliflozin to attenuate weight gain by this antidiabetes medication. Mean change from baseline in HbA1c after
adjustment for baseline value (A), mean change from baseline in urinary glucose:creatinine ratio (g/g) after adjustment for baseline value (B) and
mean change from baseline in body weight after adjustment for baseline value (C) are shown.
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(dapagliflozin 5 mg). Evidence suggestive of UTI or genital
infection occurred more frequently in women than in men.
These events were mild or moderate in intensity, with
>65% occurring in the first 24 weeks. Signs or symptoms
suggestive of UTI or genital infection responded to stan-
dard treatment typically without interruption of dapagliflo-
zin therapy and rarely led to recurrence. No events of
pyelonephritis were reported.
The proportions of renal impairment or failure events
(defined by a prespecified list) were higher with dapagliflo-
zin in total than with placebo, but similar proportions
between dapagliflozin 10 mg and placebo were reported
(Table 2). Of the 14 events (in all groups) of renal impair-
ment or failure, 8 consisted of increases in serum creatinine
≥1.5 times the baseline value, or attaining an absolute value
of 221 μmol/l. One patient in the dapagliflozin 5 mg group
had a serious adverse event of acute renal failure at day 624
due to urinary obstruction that resulted in discontinuation
and resolved following prostatectomy. Adverse events of
hypotension, or suggestive of dehydration and hypovolemia
were infrequent, non-severe, and similar between the pla-
cebo and dapagliflozin groups (Table 2). Fractures were
reported by two patients (1.5%) each in the placebo, dapa-
gliflozin 2.5 mg, and dapagliflozin 5 mg groups, and by
three patients (2.2%) in the dapagliflozin 10 mg group dur-
ing the 102-week study. One patient on dapagliflozin 5 mg
with a history of hematuria that predated randomization
experienced a bladder transitional cell cancer. One patient
on dapagliflozin 10 mg was diagnosed with breast cancer
within the first year of enrollment.
As shown in Table 3, no clinically relevant mean
changes from baseline in sodium, potassium, creatinine or
blood urea nitrogen were apparent in any treatment group
through week 102. Mean decreases from baseline in uric
acid (46 to 56 μmol/l) were noted in all dapagliflozin
groups and were significantly greater versus placebo. Small
mean increases in hemoglobin and hematocrit, which were
seen by about week 12 with dapagliflozin, remained stable
Table 2 Adverse and special interest events up to week 102
Placebo +
metformin
Dapagliflozin 2.5 mg +
metformin
Dapagliflozin
5 mg + metformin
Dapagliflozin 10 mg +
metformin
N 137 137 137 135
At least one adverse event 111 (81.0) 111 (81.0) 111 (81.0) 111 (82.2)
At least one related adverse event 28 (20.4) 36 (26.3) 33 (24.1) 45 (33.3)
Adverse event leading to
discontinuation
9 (6.6) 7 (5.1) 5 (3.6) 6 (4.4)
At least one serious adverse event 14 (10.2) 15 (10.9) 9 (6.6) 14 (10.4)
Deaths 1 (0.7) 2 (1.5) 0 0
Most common adverse events (>10% in any treatment group):
Back pain 11 (8.0) 11 (8.0) 7 (5.1) 18 (13.3)
Influenza 15 (10.9) 19 (13.9) 20 (14.6) 17 (12.6)
Diarrhea 10 (7.3) 7 (5.1) 9 (6.6) 16 (11.9)
Urinary tract infection 8 (5.8) 6 (4.4) 8 (5.8) 16 (11.9)
Headache 8 (5.8) 10 (7.3) 13 (9.5) 15 (11.1)
Nasopharyngitis 12 (8.8) 16 (11.7) 8 (5.8) 12 (8.9)
Upper respiratory tract infection 14 (10.2) 9 (6.6) 5 (3.7) 5 (3.7)
Adverse events of special interest:
Suggestive of urinary tract infection 11 (8.0) 11 (8.0) 12 (8.8) 18 (13.3)
Experiencing a single event 8/11 (72.7) 8/11 (72.7) 10/12 (83.3) 11/18 (61.1)
Men 3/76 (3.9) 2/70 (2.9) 2/69 (2.9) 4/77 (5.2)
Women 8/61 (13.1) 9/67 (13.4) 10/68 (14.7) 14/58 (24.1)
Suggestive of genital infection 7 (5.1) 16 (11.7) 20 (14.6) 17 (12.6)
Experiencing a single event 7/7 (100) 15/16 (93.8) 16/20 (80.0) 14/17 (82.4)
Men 0/76 4/70 (5.7) 4/69 (5.8) 5/77 (6.5)
Women 7/61 (11.5) 12/67 (17.9) 16/68 (23.5) 12/58 (20.7)
Renal impairment or failure 2 (1.5) 6 (4.4) 4 (2.9) 2 (1.5)
Hypoglycemia:
Total patients with hypoglycemia 8 (5.8) 5 (3.6) 7 (5.1) 7 (5.2)
Major episode of hypoglycemiaa 0 (0) 0 (0) 0 (0) 0 (0)
Hypotension, dehydration,
hypovolemia
2 (1.5) 0 (0) 3 (2.2) 2 (1.5)
Data are n (%) or n out of N (%); includes data after rescue. aMajor episode defined as a symptomatic episode requiring external assistance due to severe
impairment in consciousness or behavior with a capillary or plasma glucose value <3 mmol/l and prompt recovery after glucose or glucagon administration.
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Table 3 Summary of laboratory parameters
Placebo +
metformin (n = 137)
Dapagliflozin 2.5 mg +
metformin (n = 137)
Dapagliflozin 5 mg +
metformin (n = 137)
Dapagliflozin 10 mg +
metformin(n = 135)
Sodium (mmol/l)
N 72 77 87 93
Baseline 138.9 (2.3) 138.5 (2.9) 138.6 (2.3) 139.1 (2.2)
Change at week 102 -0.04 [2.7] 0.2 [2.8] 0.1 [2.6] 0.1 [2.6]
P vs PBO + MET 0.1434 0.1905 0.3978
Potassium (mmol/l)
n 72 77 87 93
Baseline 4.35 (0.47) 4.34 (0.46) 4.37 (0.39) 4.37 (0.43)
Change at week 102 -0.08 [0.55] -0.01 [0.45] -0.05 [0.35] -0.07 [0.47]
P vs PBO + MET 0.3366 0.4563 0.9918
Serum creatinine (μmol/l)
n 72 77 88 93
Baseline 76.9 (17.9) 78.7 (18.1) 79.6 (19.3) 77.8 (17.8)
Change at week 102 -0.9 [10.3] -1.8 [9.7] -3.5 [12.7] -2.7 [10.6]
P vs PBO + MET 0.9954 0.4720 0.9032
Serum uric acid
(μmol/l)a
n 28 35 47 57
Baseline 314 (79) 322 (80) 323 (88) 323 (80)
Change at week 102 -1.78 [54.13] -55.9 [50.32] -46.4 [64.36] -52.9 [64.36]
P vs PBO + MET 0.0054 0.0013 0.0002
Blood urea nitrogen
(mmol/l)
n 72 77 88 93
Baseline 5.33 (1.55) 5.51 (1.41) 5.65 (1.81) 5.34 (1.41)
Change at week 102 0.56 [1.24] 0.70 [1.54] 0.42 [1.87] 0.73 [1.44]
P vs PBO + MET 0.2299 0.4169 0.0845
Hematocrit (%)
n 71 78 87 93
Baseline 42.61 (3.90) 42.38 (3.99) 42.15 (3.59) 42.88 (3.95)
Change at week 102 -1.43 [3.29] 0.84 [2.53] 1.35 [2.48] 1.54 [2.78]
P vs PBO + MET <0.0001 <0.0001 <0.0001
Hemoglobin (g/l)
n 71 78 87 94
Baseline 142.8 (13.45) 142.5 (14.25) 141.6 (12.19) 143.6 (13.10)
Change at week 102 -4.9 [10.14] 1.5 [7.73] 3.1 [8.40] 4.1 [8.84]
P vs PBO + MET <0.0001 <0.0001 <0.0001
Systolic blood pressure
(mmHg)
n 72 78 88 94
Baseline 128 (15) 127 (14) 127 (14) 126 (16)
Change at week 102 1.5 [13.7] 0.7 [16.1] -1.1 [13.2] -0.3 [15.0]
P vs PBO + MET 0.1111 0.0136 0.0067
Diastolic blood pressure
(mmHg)
n 72 78 88 94
Baseline 81 (9) 80 (9) 81 (9) 79 (10)
Change at week 102 -1.0 [7.9] -0.1 [8.1] -1.5 [8.1] -1.2 [10.1]
P vs PBO + MET 0.6605 0.2140 0.1075
Data are means (SD) at baseline or mean changes [SE] from baseline at week 102 including data after rescue unless noted. n is the number of treated
patients with non-missing baseline and week 102 values for the specific test. aExcluding data after rescue. DAPA = dapagliflozin; MET = metformin; PBO =
placebo.
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thereafter. Although mean systolic and diastolic blood
pressure decreased by 2.1 to 5.1 mmHg and 1.8 to 2.5
mmHg, respectively, at 24 weeks in patients receiving
dapagliflozin (2.5 mg, 5 mg, and 10 mg) versus 0.2 and 0.1,
respectively, for placebo [9], smaller decreases from base-
line were observed at 102 weeks in mean systolic and dia-
stolic blood pressure with dapagliflozin therapy.
Discussion
In the present long-term study, dapagliflozin demon-
strated durability of glycemic and weight-loss benefits
for 102 weeks when added to metformin in patients
with type 2 diabetes who were inadequately controlled
on metformin alone, thus indicating that dapagliflozin
may be used for long-term management of excess
HbA1c and body weight. This treatment acts indepen-
dently of b-cell function or insulin sensitivity, thereby
suggesting an alternative or complementary approach to
currently available treatments and offering an additional
therapeutic option throughout the natural history of
type 2 diabetes. Recent approval by the European Medi-
cines Agency makes dapagliflozin the first agent in this
new class of SGLT2 inhibitors.
Strengths of this study include its design as a large
trial that remained double-blinded throughout the long-
term extension, unlike those conducted as open-label
extensions. A greater proportion of dapagliflozin-treated
patients remained in the trial throughout the full 2
years, substantiating the durability of the glucose-lower-
ing effect. There were no apparent baseline differences
across study groups to explain the variation in glycemic
outcomes; however, treatment-related weight reduction
is likely to be a factor in enhancement of glucose reduc-
tion. While efficacy analyses generally excluded rescue,
safety analyses included all data regardless of rescue in
order to get a comparison to placebo that was as
unbiased as possible. A potential limitation of this study
is the number of patients needing rescue medication in
the placebo group. Although this might limit the statisti-
cal interpretation of durability of the glucose-lowering
effect of dapagliflozin, it also emphasizes the clinical uti-
lity of dapagliflozin. The present study design, which
included a placebo control group for 102 weeks,
employed strict glycemic control criteria to ensure that
all patients received a quality of care consistent with
current guidelines for the treatment of type 2 diabetes.
Thus, patients whose HbA1c exceeded 7.5% at 50 weeks
or 7.0% at 76 weeks received rescue therapy and were
not included in the final efficacy analysis. Failure to
maintain a consistent decrease in blood pressure during
long-term dapagliflozin therapy may reflect the exten-
sion trial design in which investigators could adjust anti-
hypertensive therapy according to clinical need, which
may have overridden any potential blood pressure
lowering effect from dapagliflozin. In addition, the mean
baseline blood pressure was already near or at goal for
patients with diabetes.
To date, the published clinical trial data on dapagliflozin
are from short-term (12 to 24 weeks) [6,8-10] or 1-year
trials [11,13,14], all of which have demonstrated efficacy of
this agent in management of hyperglycemia. The data
from this 102-week trial demonstrate sustained glycemic
and weight-loss benefits. Because SGLT2 inhibition is an
investigative and relatively new concept within the type 2
diabetes arena, no direct comparative data with other
SGLT2 agents are available. Dapagliflozin has demon-
strated greater or augmented efficacy compared with com-
monly prescribed antidiabetic medications [6,8-11,13,14],
suggesting this novel mechanism of action may be consid-
ered as an addition to treatment options for patients with
type 2 diabetes for its advantage of having a sustained
effect in HbA1c reduction and weight loss.
The durability of type 2 diabetes therapy is typically
limited by the natural history of the disease such that the
progressive decline in b-cell function superimposed upon
insulin resistance restricts the continuing efficacy of
interventions that are dependent on insulin production
or insulin action [1]. The present study demonstrates the
increased glycemic and weight-loss benefits of the non-
insulin-dependent SGLT2 inhibition mechanism. The
low rate of discontinuations due to adverse events indi-
cates a favorable tolerability profile that makes this agent
an important addition to the treatment armamentarium.
As this is the first entry in a new class of antidiabetic
agents, dapagliflozin provides an important additional
option for clinicians managing patients with poorly con-
trolled type 2 diabetes.
A better understanding of the relationship between glu-
cosuria and genitourinary infections should be provided
with ongoing safety analyses of the dapagliflozin trial pro-
gram. Further study of the effects of dapagliflozin on
metabolic surrogate markers will assist in discrimination
of non-glycemic benefits. As an example, increased serum
uric acid is frequently associated with raised BMI, blood
pressure, FPG, and triglycerides [15,16] and has been
implicated as part of the ‘metabolic syndrome’ cluster of
risk factors for diabetes and cardiovascular complications
[17,18]. The mean decreases in serum uric acid observed
with dapagliflozin here and in other trials [5,6], which are
consistent with the uricosuric action of this agent, might
therefore indicate potential added benefits, but this
requires further investigation.
Conclusions
Dapagliflozin added to metformin over 102 weeks showed
sustained improved glycemic control, modest weight
reduction, and no increased risk of hypoglycemia in type 2
diabetes inadequately controlled with metformin alone.
Bailey et al. BMC Medicine 2013, 11:43
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These effects suggest a complementary use of the insulin
independent effects of dapagliflozin in combination with
metformin.
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